Products & Services
News & Features
Join Our Community

h-lab.jpg

All Products & Services

Research Use Only (RUO)

CE-Marked Assays

View all products

 

Wall Charts

Request a complimentary copy:

Hematologic Malignancy Testing Algorithm

Clonality Testing Strategy

 

 

IMPORTANT NOTICE:

If you are an acute myeloid leukemia patient
who is either contemplating participation in,
or currently participating in a clinical trial
that involves a drug that requires FLT3
testing, make sure you verify with your
physician that your FLT3 test is being
performed by LabPMM.

LabPMM is the only testing facility properly
authorized to generate a valid FLT3 result
that can be used toward regulatory
approval of a companion diagnostic.

The FDA has made it clear that approval
of any FLT3 targeted therapy will require
an FDA-approved companion diagnostic.

Are you willing and BCR/ABL?
Leading clinical laboratories from around the world are participating in our international BCR/ABL RT-QPCR standardization & harmonization project, "Are you willing and BCR/ABL?"

More than fifty participants have completed the survey, received test materials and, as of the end of July, thirty-four participants have sent back their data.  These laboratories will receive their laboratory's, our laboratory's, and the group's anonymized test results by August 2nd. It is not too late to take part in this important study. To learn more on how you can participate please contact: bcrablproject@invivoscribe.com

Personalized Medicine & IVS
Invivoscribe is a leading provider of clinically-validated CE-marked in vitro diagnostic products. Through our subsidiary, the Laboratory for Personalized Molecular Medicine (LabPMM), we provide worldwide access to state of the art personalized molecular testing to physicians and cancer centers, enabling doctors to determine optimal treatment for each individual patient.

Research & Biotechnology
Development & Partnering

Upcoming Meetings and Conferences

AMP_LOGO.jpgNovember 17-20, 2010
AMP 2010 Annual Meeting, San Jose, CA USA

ash.jpgDecember 4-7, 2010
52nd ASH Annual Meeting, Orlando, FL USA

View all Events

 

Invivoscribe announces collaboration with ATCC

Invivoscribe has entered into a comprehensive agreement with American Type Culture Collection (ATCC) to standardize controls.

View all Press Releases

 

Invivoscribe developing companion diagnostic products

Invivoscribe is committed to new regulatory requirements that include development of companion diagnostics for new therapeutic agents.  Our first companion diagnostic will identify FLT3 mutations in patients with acute myeloid leukemia. Contact us to learn more about our program for development of companion diagnostic products.

 h-fb.gif  h-twitter.gif  h-newsvine.gif  
 
Invivoscribe Companies
h-labPMM-logo.gif
h-amlalliance.gif
ivs-labflow.gif
h-ivs-sarl.gif
web design by specto design